IP Library › Granted Patent US 9,856,292
Granted Patent B2
US 9,856,292 · App. 14/938,327 · Granted Jan 2, 2018

Immunomodulators

Inventors: Kevin W. Gillman (Madison, CT); Jason Goodrich (Wallingford, CT); Kenneth M. Boy (Durham, CT); Yunhui Zhang (Glastonbury, CT); Claudio Mapelli (Lawrenceville, NJ); Michael A. Poss (Lawrenceville, NJ); Paul Michael Scola (Glastonbury, CT); David R. Langley (Meriden, CT); Nicholas A. Meanwell (East Hampton, CT)
Assignee: Bristol-Myers Squibb Company
C07K7/08A61K38/10A61K45/06C07K7/56A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,856,292
App. No.
14/938,327
Granted
Jan 2, 2018
Kind
B2
Abstract

The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.

Claims (99)

1. A compound of formula (I)

or a pharmaceutically acceptable salt thereof, wherein:

A is

wherein:

denotes the point of attachment to the carbonyl group and denotes the point of attachment to the nitrogen atom;

m is 1;

w is 0, 1, or 2;

R 14 and R 15 are hydrogen;

R 16a is hydrogen;

R 16 is selected from

—CH 2 C(O)NHCH(R 17 )C(O)NH 2 ;

—CH 2 C(O)NHCH(R 17 )C(O)NHCH(R 17a )C(O)NH 2 ; and

—CH 2 C(O)NHCH(R 17 )CO 2 H;

wherein:

X is selected from

—(CH 2 ) 2 CH(CO 2 H)NHC(O)(CH 2 ) p ;

—(CH 2 CH 2 O) q ; and

—(CH 2 CH 2 O) q CH 2 CH 2 NHC(O)CH 2 CH 2 CH(CO 2 H)NHC(O)(CH 2 ) p ;

wherein q is 3, 4, 5, 6, 7, 8, 9, 10, or 11; and

wherein p is 14, 15, or 16;

each R 17a is independently selected from hydrogen and —CH 2 CO 2 H,

each R 17 is —(CH 2 ) z -triazolyl-X—R 35 , wherein z is 1 and R 35 is selected from —CO 2 H and CH 3 ,

R c , R f , R h , R i , R m , and R n are hydrogen;

R a , R e , and R j , are hydrogen;

R b , R k , and R l are methyl;

R 1 is phenylC 1 -C 3 alkyl wherein the phenyl part is optionally substituted with hydroxy, halo, or methoxy;

R 2 is C 1 -C 7 alkyl;

R 3 is amidoC 1 -C 3 alkyl or carboxyC 1 -C 3 alkyl;

R 4 and R d , together with the atoms to which they are attached, form a pyrrolidine ring;

R 5 is selected from imidazolylC 1 -C 3 alkyl, aminoC 1 -C 3 alkyl, and aminobutyl;

R 6 is selected from amidoC 1 -C 3 alkyl, aminoC 1 -C 3 alkyl, aminobutyl, and C 1 -C 7 alkyl;

R 7 and R g , together with the atoms to which they are attached, form a pyrrolidine ring optionally substituted with hydroxy;

R 8 and R 10 are indolylC 1 -C 3 alkyl optionally substituted with carboxyC 1 -C 3 alkyl;

R 9 is hydroxyC 1 -C 3 alkyl or aminoC 1 -C 3 alkyl;

R 11 is C 1 -C 7 alkyl;

R 12 is C 1 -C 7 alkyl; and

R 13 is selected from C 1 -C 7 alkyl, carboxyC 1 -C 3 alkyl, and —(CH 2 ) 3 NHC(NH)NH 2 .

2. A compound which is

or a pharmaceutically acceptable salt thereof.

3. A compound which is

or a pharmaceutically acceptable salt thereof.

4. A compound which is

or a pharmaceutically acceptable salt thereof.

5. A compound which is

or a pharmaceutical acceptable salt thereof.

6. A compound which is

or a pharmaceutically acceptable salt thereof.

7. A compound which is

or a pharmaceutically acceptable salt thereof.

8. A compound which is

or a pharmaceutically acceptable salt thereof.

9. A compound which is

or a pharmaceutically acceptable salt thereof.

10. A compound which is

or a pharmaceutically acceptable salt thereof.

11. A compound which is

or a pharmaceutically acceptable salt thereof.

12. A compound which is

or a pharmaceutically acceptable salt thereof.

13. A compound which is

or a pharmaceutically acceptable salt thereof.

14. A compound which is

or a pharmaceutically acceptable salt thereof.

15. A compound which is

or a pharmaceutically acceptable salt thereof.

16. A compound which is

or a pharmaceutically acceptable salt thereof.

17. A compound which is

or a pharmaceutically acceptable salt thereof.

18. A compound which is

or a pharmaceutically acceptable salt thereof.

19. A compound which is

or a pharmaceutically acceptable salt thereof.

20. A compound which is

or a pharmaceutically acceptable salt thereof.

21. A compound which is

or a pharmaceutically acceptable salt thereof.

22. A compound which is

or a pharmaceutically acceptable salt thereof.

23. A compound which is

or a pharmaceutically acceptable salt thereof.

24. A compound which is

or a pharmaceutically acceptable salt thereof.

25. A compound which is

or a pharmaceutically acceptable salt thereof.

26. A compound which is

or a pharmaceutically acceptable salt thereof.

27. A compound which is

or a pharmaceutically acceptable salt thereof.

28. A compound which is

or a pharmaceutically acceptable salt thereof.

29. A compound which is

or a pharmaceutically acceptable salt thereof.

30. A compound which is

or a pharmaceutically acceptable salt thereof.

31. A compound which is

or a pharmaceutically acceptable salt thereof.

32. A compound which is

or a pharmaceutically acceptable salt thereof.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 23, 2017
From: MEANWELL, NICHOLAS A.
To: BRISTOL-MYERS SQUIBB COMPANY
Reel/Frame 042794/0536 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 19, 2017
From: LANGLEY, DAVID R.
To: BRISTOL-MYERS SQUIBB COMPANY
Reel/Frame 042437/0786 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 2, 2015
From: GILLMAN, KEVIN W.; GOODRICH, JASON; BOY, KENNETH M.; ZHANG, YUNHUI; MAPELLI, CLAUDIO; POSS, MICHAEL A.; SUN, LI-QIANG; ZHAO, QIAN; MULL, ERIC; GILLIS, ERIC P.; SCOLA, PAUL MICHAEL
To: BRISTOL-MYERS SQUIBB COMPANY
Reel/Frame 037194/0523 →
Continuity (4)
Provisional Application 62204689 · Aug 13, 2015
Provisional Application 62111388 · Feb 3, 2015
Provisional Application 62079944 · Nov 14, 2014
Related Publication 20160137696A1 · May 19, 2016